Multiple myeloma (MM) is a haematological malignancy caused by malignant proliferation of plasma cells in bone marrow. In recent years, MM patients are commonly treated with chemotherapy, autologous stem cell transplantation, protease inhibitors, immunomodulatory drugs and monoclonal antibodies, however most patients eventually relapse. Therefore, more effective therapies are highly needed. Anti‐BCMA CAR‐T therapy, a novel and efficacious method for treating MM and relapsed/refractory multiple myeloma (RRMM), has been designed and applied in clinics. The CAR‐T can specifically recognize the targeted molecule B cell maturation antigen (BCMA) and kill MM cells expressing BCMA and several clinical trials have revealed high response rates in the therapy. Herein, we summarize the developments, the current design and clinical trials, the side effects of anti‐BCMA CAR‐T therapy and comparison of it with other CAR‐T therapies.

中文翻译：

---

用于多发性骨髓瘤和复发/难治性多发性骨髓瘤的抗BCMA CAR-T免疫疗法概述。

多发性骨髓瘤（MM）是由骨髓中浆细胞的恶性增殖引起的血液系统恶性肿瘤。近年来，MM患者通常接受化疗，自体干细胞移植，蛋白酶抑制剂，免疫调节药物和单克隆抗体治疗，但是大多数患者最终会复发。因此，迫切需要更有效的疗法。抗BCMA CAR-T治疗是一种新颖有效的治疗MM和复发/难治性多发性骨髓瘤（RRMM）的方法，已在临床中设计并应用。CAR‐T可以特异性识别目标分子B细胞成熟抗原（BCMA）并杀死表达BCMA的MM细胞，多项临床试验显示该疗法具有很高的反应率。在此，我们总结了开发情况，当前的设计和临床试验，